Follow-up of Symphony and Prodigy devices for removing blood clots
Follows how Symphony and Prodigy clot-removal devices work and stay safe in adults.
Key facts
- Who runs it
- Imperative Care, Inc.
- Where
- Buffalo, Cincinnati, Clearwater, Detroit, Fort Worth, Huntsville, Jacksonville, Munster, Naperville, New York, Norfolk, Raleigh, and Tampa, United StatesSee the 13 sites
- Trial code
- Registry title
- Aspiration Thrombectomy Using the Symphony or Prodigy System
- Status
- Recruiting
- People taking part
- 750 people, planned
- Started
- 13 Feb 2026
- Expected to end
- Sept 2030
- Type of study
- Observational, 3 groups
- Treatments tested
- Prodigy Thrombectomy System
- Symphony Thrombectomy System
- Record updated
- 22 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a blood clot in the arteries or veins of the arms or legs, or in the lungs. They must have a planned procedure to suck out the clot with the Symphony or Prodigy device.
- Age
- 18 years or older
- Sex
- All sexes
- Disease stage
- Blood clots in the peripheral arteries, peripheral veins or lung blood vessels (pulmonary embolism)
Main reasons for not taking part
- Any reason the device instructions say it must not be used
- Expected to live less than 1 year
- The study doctor thinks the procedure with these devices is not right for the person
- May not be able to finish the study follow-up visits
- Vein group only: a clot reaching more than 2 cm (0.8 in) into the large belly vein (IVC) on scans
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Subject is ≥ 18 years of age
- Subject is willing and able to comply with the follow-up schedule specified in this protocol
- Subject is willing and able to provide written informed consent prior to any study-related data collection
- Subject has a planned procedure, involving the use of Imperative Care vascular devices within their intended use
Who cannot take part
- Subjects with any contraindications per the applicable Instructions for Use
- Subject with life expectancy of less than 1 year
- In the opinion of the Investigator, the patient is not a suitable candidate for intervention with Imperative Care devices
- Subject who may be unable to complete study follow-up
- Peripheral Venous Cohort ONLY: Presence of thrombus extending more than 2 cm into the IVC on imaging
Where in United States
- University at BuffaloBuffalo, United StatesContact: Sylvie Akiel-Fu, MPHTaking people
- Mercy HealthCincinnati, United StatesContact: Sylvie Akiel-Fu, MPHTaking people
- BayCare Health System / Morton Plant HospitalClearwater, United StatesContact: Sylvie Akiel-Fu, MPHTaking people
- Henry Ford HospitalDetroit, United StatesContact: Sylvie Akiel-Fu, MPHTaking people
- Medical City Fort Worth HospitalFort Worth, United StatesContact: Sylvie Akiel-Fu, MPHTaking people
- Huntsville HospitalHuntsville, United StatesContact: Sylvie Akiel-Fu, MPHTaking people
- HCA Florida Memorial HospitalJacksonville, United StatesContact: Sylvie Akiel-Fu, MPHTaking people
- Profound ResearchMunster, United StatesContact: Sylvie Akiel-Fu, MPHTaking people
- Midwest Cardiovascular InstituteNaperville, United StatesContact: Sylvie Akiel-Fu, MPHTaking people
- Mount Sinai HospitalNew York, United StatesContact: Sylvie Akiel-Fu, MPHTaking people
- Sentara Norfolk General HospitalNorfolk, United StatesContact: Sylvie Akiel-Fu, MPHTaking people
- NC Heart and Vascular ResearchRaleigh, United StatesContact: Sylvie Akiel-Fu, MPHTaking people
- BayCare Health System - St. Joseph HospitalTampa, United StatesContact: Sylvie Akiel-Fu, MPHTaking people
About the trial
What the trial wants to find out
The study is designed to evaluate the short-term and long-term clinical performance and safety of the Symphony and Prodigy thrombectomy systems used in endovascular procedures across the peripheral or pulmonary vasculature.
The 3 groups in the trial
- Peripheral Arterial
Subjects in this cohort will undergo aspiration thrombectomy to remove thrombus from the peripheral arterial vasculature
Treatment: Prodigy Thrombectomy System
- Peripheral Venous
Subjects in this cohort will undergo aspiration thrombectomy to remove thrombus from the peripheral venous vasculature
Treatment: Symphony Thrombectomy System
- Pulmonary Embolism
Subjects in this cohort will undergo aspiration thrombectomy to remove thrombus from the pulmonary vasculature
Treatment: Symphony Thrombectomy System
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Long-Term CLinical Evaluation of Aspiration ThRombectomy Using the Symphony or ProdIgy Thrombectomy System - CLEAR-IT
- Plain-language title
- Follow-up of Symphony and Prodigy devices for removing blood clotsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Record updated
- 22 October 2026